Steroid-resistant sarcoidosis has conventionally been treated with various drugs, including methotrexate, azathioprine, cyclophosphamide, cyclosporine, antimalarial drugs and thalidomide, with variable success. There is a compelling need for more efficient and safer alternatives to these agents. Several lines of evidence suggest a critical role of TNF-α (tumour necrosis factor-α) in the initiation and organization of sarcoid granulomas. Inhibition of TNF-α with monoclonal antibodies has therefore received attention as a potential treatment option in therapy-resistant sarcoidosis. A number of case reports and small case series describe successful treatment of refractory disease with infliximab. Preliminary evidence from an RCT (randomized controlled trial) with infliximab in pulmonary sarcoidosis suggests a modest improvement in functional and radiological parameters. In contrast, the results with etanercept have been disappointing, perhaps related to differences in the mechanism of TNF-α blockade. The experience with adalimumab in sarcoidosis is too limited to draw conclusions. An open-label study and an RCT evaluating the efficacy of adalimumab in sarcoidosis with pulmonary and cutaneous involvement respectively, have been initiated. Although TNF-α antagonists appear relatively safe, especially when compared with conventional agents, caution is warranted in view of the increased incidence of tuberculosis, which may be a particular diagnostic challenge in patients with sarcoidosis. Pending publication of the RCTs, the use of TNF-α blockade in sarcoidosis should remain in the realm of experimental treatment.
Skip Nav Destination
Article navigation
March 2007
-
Cover Image
Cover Image
- PDF Icon PDF LinkTable of Contents
Review Article|
February 01 2007
Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer? Available to Purchase
Bart G. Denys;
Bart G. Denys
*Department of Internal Medicine, AZ Sint-Jan AV, Ruddershove 10, B-8000 Brugge, Belgium
Search for other works by this author on:
Yves Bogaerts;
Yves Bogaerts
†Department of Pneumology, AZ Sint-Jan AV, Ruddershove 10, B-8000 Brugge, Belgium
Search for other works by this author on:
Kenneth L. Coenegrachts;
Kenneth L. Coenegrachts
‡Department of Radiology, AZ Sint-Jan AV, Ruddershove 10, B-8000 Brugge, Belgium
Search for other works by this author on:
An S. De Vriese
*Department of Internal Medicine, AZ Sint-Jan AV, Ruddershove 10, B-8000 Brugge, Belgium
Correspondence: Dr An S. De Vriese (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
April 25 2006
Revision Received:
July 13 2006
Accepted:
August 08 2006
Online ISSN: 1470-8736
Print ISSN: 0143-5221
The Biochemical Society
2007
Clin Sci (Lond) (2007) 112 (5): 281–289.
Article history
Received:
April 25 2006
Revision Received:
July 13 2006
Accepted:
August 08 2006
Citation
Bart G. Denys, Yves Bogaerts, Kenneth L. Coenegrachts, An S. De Vriese; Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer?. Clin Sci (Lond) 1 March 2007; 112 (5): 281–289. doi: https://doi.org/10.1042/CS20060094
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |